Fairmount Funds Management LLC has demonstrated a clear selling bias in its recent insider transactions, with $503.5 million in total sales outweighing $86 million in purchases across 24 filings. The firm’s activity has concentrated heavily on biotechnology and life sciences holdings, particularly Cogent Biosciences (COGT), which accounted for two major sell-side transactions: a $242.6 million disposition on March 31, 2026, and a $127.4 million sale on January 22, 2026. These large-scale exits from COGT contrast with Fairmount’s earlier $25 million acquisition of the stock in July 2025. The firm also divested its entire $133.5 million position in Apogee Therapeutics (APGE) in January 2026, further reinforcing the sell-off trend among its core holdings.
On the buy side, Fairmount’s acquisitions have been smaller and more targeted, focusing on stakes in emerging biotech names. Notable purchases included a $18.2 million investment in Catalyst Biosciences (CBIO) in December 2025 and a $10 million position in Viridian Therapeutics (VRDN) the previous October. The firm also accumulated shares in ZBIO and JBIO during late 2025, though these positions were modest compared to its later COGT and APGE liquidations. While Fairmount executed five buys versus three sells in recent months, the dollar volume skews decisively toward exits, suggesting a strategic reduction in certain high-value biotech exposures while maintaining smaller growth-oriented bets. The absence of material transactions in early 2026 outside of the COGT sales may indicate a period of portfolio consolidation.
AI-assisted summary